{"disease":{"id":"deep-vein-thrombosis","name":"Deep vein thrombosis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":3,"pipeline_drug_count":0,"trial_count":4},"drugs":{"marketed":[{"drug_id":"edoxaban","indication_name":"Prevention of deep vein thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Savaysa","generic_name":"edoxaban","company_name":"Daiichi Sankyo Inc","drug_phase":"marketed","molecular_target":"Coagulation factor X","drug_class":"Factor Xa Inhibitor","quality_score":73,"revenue":"1800","mechanism":"Savaysa works by blocking the action of coagulation factor X, a key protein involved in blood clotting."},{"drug_id":"dabigatran","indication_name":"Deep vein thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pradaxa","generic_name":"dabigatran etexilate","company_name":"Generic (originally Boehringer Ingelheim)","drug_phase":"marketed","molecular_target":"Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone]","drug_class":"Direct oral anticoagulant (DOAC) — direct thrombin inhibitor","quality_score":69,"revenue":"1200","mechanism":"Direct thrombin inhibitor that blocks both free and clot-bound thrombin, providing anticoagulation without routine monitoring."},{"drug_id":"dabigatran","indication_name":"Prevention of deep vein thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pradaxa","generic_name":"dabigatran etexilate","company_name":"Generic (originally Boehringer Ingelheim)","drug_phase":"marketed","molecular_target":"Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone]","drug_class":"Direct oral anticoagulant (DOAC) — direct thrombin inhibitor","quality_score":69,"revenue":"1200","mechanism":"Direct thrombin inhibitor that blocks both free and clot-bound thrombin, providing anticoagulation without routine monitoring."},{"drug_id":"fondaparinux","indication_name":"Prevention of deep vein thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arixtra","generic_name":"FONDAPARINUX","company_name":"Mylan Ireland Ltd","drug_phase":"marketed","molecular_target":"Coagulation factor X","drug_class":"Factor Xa Inhibitor","quality_score":67,"revenue":null,"mechanism":"Arixtra works by blocking the action of factor Xa, a protein involved in blood clotting."},{"drug_id":"heparin","indication_name":"Deep Vein Thrombosis with Pulmonary Embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Heparin Sodium In Plastic Container","generic_name":"HEPARIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"Anti-coagulant","quality_score":56,"revenue":null,"mechanism":"Heparin works by binding to Antithrombin-III, a protein that inhibits the formation of blood clots."},{"drug_id":"heparin","indication_name":"Prevention of deep vein thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Heparin Sodium In Plastic Container","generic_name":"HEPARIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"Anti-coagulant","quality_score":56,"revenue":null,"mechanism":"Heparin works by binding to Antithrombin-III, a protein that inhibits the formation of blood clots."},{"drug_id":"rivaroxaban","indication_name":"Prevention of deep vein thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xarelto","generic_name":"rivaroxaban","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Factor Xa (FXa)","drug_class":"Direct Factor Xa Inhibitor","quality_score":71,"revenue":null,"mechanism":"Selective FXa inhibitor that decreases thrombin generation without requiring cofactors."},{"drug_id":"dabigatran-etexilate","indication_name":"Deep vein thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pradaxa","generic_name":"dabigatran-etexilate","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Thrombin (serine protease)","drug_class":"Direct thrombin inhibitor","quality_score":71,"revenue":null,"mechanism":"Competitive direct thrombin inhibitor preventing fibrin formation and thrombus development."},{"drug_id":"dabigatran-etexilate","indication_name":"Prevention of deep vein thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pradaxa","generic_name":"dabigatran-etexilate","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Thrombin (serine protease)","drug_class":"Direct thrombin inhibitor","quality_score":71,"revenue":null,"mechanism":"Competitive direct thrombin inhibitor preventing fibrin formation and thrombus development."},{"drug_id":"dabigatran-etexilate-de","indication_name":"Deep vein thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dabigatran etexilate (DE)","generic_name":"dabigatran-etexilate-de","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone]","drug_class":"Dabigatran etexilate (DE) as oral capsule","quality_score":null,"revenue":null,"mechanism":"Dabigatran etexilate (DE) as oral capsule"},{"drug_id":"fragmin","indication_name":"Prophylaxis of deep vein thrombosis in patients undergoing hip replacement surgery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fragmin","generic_name":"Dalteparin Sodium","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Factor Xa and thrombin","drug_class":"Low molecular weight heparin (LMWH)","quality_score":68,"revenue":null,"mechanism":"Dalteparin enhances inhibition of Factor Xa and thrombin by antithrombin."},{"drug_id":"fragmin","indication_name":"Prophylaxis of deep vein thrombosis in patients undergoing abdominal surgery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fragmin","generic_name":"Dalteparin Sodium","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Factor Xa and thrombin","drug_class":"Low molecular weight heparin (LMWH)","quality_score":68,"revenue":null,"mechanism":"Dalteparin enhances inhibition of Factor Xa and thrombin by antithrombin."},{"drug_id":"fragmin","indication_name":"Prophylaxis of deep vein thrombosis in medical patients with severely restricted mobility during acute illness","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fragmin","generic_name":"Dalteparin Sodium","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Factor Xa and thrombin","drug_class":"Low molecular weight heparin (LMWH)","quality_score":68,"revenue":null,"mechanism":"Dalteparin enhances inhibition of Factor Xa and thrombin by antithrombin."},{"drug_id":"heparin-sodium","indication_name":"Deep Vein Thrombosis with Pulmonary Embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Heparin Sodium In Plastic Container","generic_name":"Heparin Sodium","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"Antithrombin III, Coagulation Factors Xa and IIa","drug_class":"Anticoagulant","quality_score":63,"revenue":null,"mechanism":"Heparin enhances Antithrombin III activity to inhibit coagulation factors Xa and IIa."},{"drug_id":"heparin-sodium","indication_name":"Prevention of deep vein thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Heparin Sodium In Plastic Container","generic_name":"Heparin Sodium","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"Antithrombin III, Coagulation Factors Xa and IIa","drug_class":"Anticoagulant","quality_score":63,"revenue":null,"mechanism":"Heparin enhances Antithrombin III activity to inhibit coagulation factors Xa and IIa."},{"drug_id":"warfarin","indication_name":"Deep Vein Thrombosis with Pulmonary Embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Coumadin","generic_name":"warfarin","company_name":"Generic (originally Wisconsin Alumni Research Foundation)","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase complex subunit 1-like protein 1, Cytochrome P450 2C9, Proprotein convertase subtilisin/kexin type 7","drug_class":"Vitamin K antagonist (anticoagulant)","quality_score":60,"revenue":null,"mechanism":"Inhibits vitamin K epoxide reductase, blocking the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) to prevent thrombosis."},{"drug_id":"warfarin","indication_name":"Prevention of deep vein thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Coumadin","generic_name":"warfarin","company_name":"Generic (originally Wisconsin Alumni Research Foundation)","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase complex subunit 1-like protein 1, Cytochrome P450 2C9, Proprotein convertase subtilisin/kexin type 7","drug_class":"Vitamin K antagonist (anticoagulant)","quality_score":60,"revenue":null,"mechanism":"Inhibits vitamin K epoxide reductase, blocking the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) to prevent thrombosis."},{"drug_id":"arixtra","indication_name":"Prevention of deep vein thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Arixtra","company_name":"LifeBridge Health","drug_phase":"marketed","molecular_target":"Antithrombin-III, Coagulation factor X","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"desirudin","indication_name":"Prevention of deep vein thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Revasc","generic_name":"DESIRUDIN","company_name":"Marathon Pharms Llc","drug_phase":"marketed","molecular_target":"Prothrombin","drug_class":"Anti-coagulant","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"dabigatran-etexilate-de","indication_name":"Prevention of deep vein thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dabigatran etexilate (DE)","generic_name":"dabigatran-etexilate-de","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone]","drug_class":"Dabigatran etexilate (DE) as oral capsule","quality_score":null,"revenue":null,"mechanism":"Dabigatran etexilate (DE) as oral capsule"},{"drug_id":"xarelto","indication_name":"Prevention of deep vein thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xarelto","company_name":"University Hospital, Montpellier","drug_phase":"marketed","molecular_target":"Suppressor of tumorigenicity 14 protein, Coagulation factor X, Coagulation factor X","drug_class":"","quality_score":19,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":21,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04969653","title":"The Incidence of Venous Thromboembolism in Atopic Dermatitis","phase":"","overall_status":"COMPLETED","enrollment_count":754745,"lead_sponsor_name":"Momentum Data","has_results":true},{"nct_id":"NCT04838106","title":"Outcomes of Patients Who Survived Treatment on an Intensive Care Unit for COVID-19 in England and Wales","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":319600,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT03835780","title":"The Risk of Venous Thromboembolism in Systemic Inflammatory Disorders: a United Kingdom (UK) Matched Cohort Study","phase":"","overall_status":"COMPLETED","enrollment_count":266890,"lead_sponsor_name":"Momentum Data","has_results":true},{"nct_id":"NCT06232551","title":"Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism","phase":"NA","overall_status":"RECRUITING","enrollment_count":152000,"lead_sponsor_name":"Scott C. Woller, MD","has_results":false},{"nct_id":"NCT05083455","title":"Replication of the RECORD1 Anticoagulant Trial in Healthcare Claims Data","phase":"","overall_status":"COMPLETED","enrollment_count":89215,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT04574895","title":"Using a Real-Time Risk Prediction Model to Predict Pediatric Venous Thromboembolism (VTE) Events","phase":"NA","overall_status":"COMPLETED","enrollment_count":17427,"lead_sponsor_name":"Vanderbilt University Medical Center","has_results":false},{"nct_id":"NCT02155491","title":"Global Anticoagulant Registry in the FIELD- Venous Thromboembolic Events","phase":"","overall_status":"COMPLETED","enrollment_count":10679,"lead_sponsor_name":"Thrombosis Research Institute","has_results":false},{"nct_id":"NCT06581965","title":"inDividual, Targeted thrombosIS Prophylaxis Versus the Standard 'One Size Fits All' Approach in Patients Undergoing Total hIp or Total kNee replaCemenT","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":10078,"lead_sponsor_name":"Leiden University Medical Center","has_results":false},{"nct_id":"NCT04400877","title":"Prevalence and Severity of Venous Thromboembolism in a General Population During the COVID-19 Pandemic","phase":"","overall_status":"COMPLETED","enrollment_count":7795,"lead_sponsor_name":"University Hospital, Linkoeping","has_results":false},{"nct_id":"NCT02600260","title":"Thromboprophylaxis in Pregnant Women in Hospital: A Prospective Clinical Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":7212,"lead_sponsor_name":"University of Sao Paulo General Hospital","has_results":false},{"nct_id":"NCT03881345","title":"Ongoing Registry of Treatment of Venous Thromboembolism","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Medalp Private Surgery Clinic","has_results":false},{"nct_id":"NCT03129555","title":"The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Herlev and Gentofte Hospital","has_results":false},{"nct_id":"NCT03483181","title":"Thromboprophylaxis in Patients Undergoing Orthopedic Surgeries; Using Propensity Score Matching","phase":"","overall_status":"UNKNOWN","enrollment_count":4000,"lead_sponsor_name":"Hanoi Medical University","has_results":false},{"nct_id":"NCT03650127","title":"Returning Genome and Metabolome Data to FinTerveys 2017 Participants: P5.fi FinTerveys Study","phase":"","overall_status":"UNKNOWN","enrollment_count":3449,"lead_sponsor_name":"Markus Perola","has_results":false},{"nct_id":"NCT06727669","title":"Longitudinal Cohort of Thrombosis and Hemostasis Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT03919305","title":"Cerebral Venous Thrombosis Cohort Study in China Mainland","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Capital Medical University","has_results":false},{"nct_id":"NCT06989255","title":"A Multi-center Cohort Study for Conventional Ultrasound Image Set Collection to Create a Data Set for Research Purposes.","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"ThrombUS+","has_results":false},{"nct_id":"NCT06370702","title":"Evaluating the Use of Grip Exercises to Decrease Deep Vein Thrombosis in Adult Patients With PICC Lines","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":2500,"lead_sponsor_name":"TriHealth Inc.","has_results":false},{"nct_id":"NCT06648837","title":"Microvisk Continuous Blood Donation Study","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":2500,"lead_sponsor_name":"Microvisk Technologies Ltd","has_results":false},{"nct_id":"NCT06468150","title":"Mechanical Thrombectomy and Catheter Directed Thrombolysis Utilization in Patients With Deep Vein Thrombosis","phase":"","overall_status":"COMPLETED","enrollment_count":2427,"lead_sponsor_name":"Pirogov Russian National Research Medical University","has_results":false},{"nct_id":"NCT04330170","title":"Inferior Vena Cava Filters: Analysis of a Database","phase":"","overall_status":"COMPLETED","enrollment_count":2399,"lead_sponsor_name":"Pirogov Russian National Research Medical University","has_results":false},{"nct_id":"NCT06258694","title":"Venous Thrombo-Embolism Imaging Database (VTE-ID)","phase":"","overall_status":"COMPLETED","enrollment_count":2208,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT06009484","title":"VTE Incidence After Curative Colon Cancer Surgery in an ERAS Program","phase":"","overall_status":"COMPLETED","enrollment_count":2141,"lead_sponsor_name":"Nordsjaellands Hospital","has_results":false},{"nct_id":"NCT02210819","title":"Treatment of Venous Thromboembolism (VTE) With Either Rivaroxaban or Current Standard of Care Therapy","phase":"","overall_status":"COMPLETED","enrollment_count":1987,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06195540","title":"RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1424,"lead_sponsor_name":"University Hospital, Angers","has_results":false},{"nct_id":"NCT04439383","title":"Risk Stratification for Venous Thromboembolism in Hospitalized Medical Patients","phase":"","overall_status":"COMPLETED","enrollment_count":1353,"lead_sponsor_name":"Insel Gruppe AG, University Hospital Bern","has_results":false},{"nct_id":"NCT06246604","title":"Screening for Deep Vein Thrombosis in Intensive Care","phase":"NA","overall_status":"UNKNOWN","enrollment_count":1300,"lead_sponsor_name":"University Of Perugia","has_results":false},{"nct_id":"NCT04981327","title":"The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":1300,"lead_sponsor_name":"University Hospital, Geneva","has_results":false},{"nct_id":"NCT07330661","title":"Nursing-Led Deep Vein Thrombosis Prevention in Neurosurgery","phase":"NA","overall_status":"COMPLETED","enrollment_count":1286,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT05476913","title":"GEKO Venous Thromboembolism Prevention Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":1200,"lead_sponsor_name":"Firstkind Ltd","has_results":false},{"nct_id":"NCT02073682","title":"Cancer Venous Thromboembolism (VTE)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1046,"lead_sponsor_name":"Daiichi Sankyo","has_results":true},{"nct_id":"NCT05905874","title":"Machine Learning-based Models in Prediction of DVT and PTE in AECOPD Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT06842446","title":"Systematic Machine Learning Algorithm for Rapid Thrombosis Detection","phase":"NA","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Ostfold Hospital Trust","has_results":false},{"nct_id":"NCT04373707","title":"Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT07439991","title":"Study of Risk Factors and Prediction of Blood Clots After Lung Cancer Surgery","phase":"","overall_status":"RECRUITING","enrollment_count":900,"lead_sponsor_name":"The First Hospital of Jilin University","has_results":false},{"nct_id":"NCT06365528","title":"Tunneled Peripherally Inserted Central Catheter (PICC) in Adult Patients and Associated Outcomes","phase":"NA","overall_status":"RECRUITING","enrollment_count":840,"lead_sponsor_name":"Hospital de Clinicas de Porto Alegre","has_results":false},{"nct_id":"NCT05224388","title":"Evaluating Dose Regimen of Intravenous Unfractionated Heparin and Low Molecular Weight Heparin in Critical Ill Patients Versus Critical Ill COVID-19 Patients Using Anti-Xa Levels.","phase":"","overall_status":"COMPLETED","enrollment_count":813,"lead_sponsor_name":"University Hospital, Ghent","has_results":false},{"nct_id":"NCT02744092","title":"Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":811,"lead_sponsor_name":"Alliance Foundation Trials, LLC.","has_results":true},{"nct_id":"NCT02297373","title":"Clinical Predictors for Venous Thromboembolism in Patients With a History of Thrombosis (PREDICTORS)","phase":"","overall_status":"COMPLETED","enrollment_count":744,"lead_sponsor_name":"Ottawa Hospital Research Institute","has_results":true},{"nct_id":"NCT04917328","title":"Compression Ultrasonography in Non-high Probability of Deep Vein Thrombosis","phase":"NA","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"University Hospital, Strasbourg, France","has_results":false},{"nct_id":"NCT04393909","title":"Improving Safety of Diagnosis and Therapy in the Inpatient Setting","phase":"NA","overall_status":"COMPLETED","enrollment_count":700,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT06652568","title":"Determining the Validity of ThinkSono Guidance for Ultrasound Image Acquisition and Remote Detection","phase":"NA","overall_status":"COMPLETED","enrollment_count":634,"lead_sponsor_name":"ThinkSono, Ltd.","has_results":true},{"nct_id":"NCT06087952","title":"Leiden Thrombosis Recurrence Risk Prevention","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":608,"lead_sponsor_name":"Leiden University Medical Center","has_results":false},{"nct_id":"NCT04168203","title":"Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":600,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":true},{"nct_id":"NCT05356767","title":"The Study of Percutaneous Mechanical Thrombectomy Treating Acute Deep Vein Thrombosis of Lower Extremities","phase":"","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"Chengdu University of Traditional Chinese Medicine","has_results":false},{"nct_id":"NCT04865913","title":"Venous Thrombosis Virtual Surveillance in COVID-19","phase":"","overall_status":"COMPLETED","enrollment_count":510,"lead_sponsor_name":"Ottawa Hospital Research Institute","has_results":false},{"nct_id":"NCT03056196","title":"Two-Site Compression POINt-OF-CARE Ultrasonography for DVT","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Jewish General Hospital","has_results":false},{"nct_id":"NCT05464901","title":"VTE and the Related Factors Associated With Higher Rates of PE After a DVT in Southwestern China","phase":"","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"Wei Huang","has_results":false},{"nct_id":"NCT05680636","title":"New Clinical Score for Deep Vein Thrombosis","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Accademia Italiana Medicina Osteopatica","has_results":false},{"nct_id":"NCT03909399","title":"Prevention and Prophylaxis of Cancer Associated Thrombosis in High Risk Oncology Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Hellenic Society of Medical Oncology","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}